PDS Biotechnology (PDSB) Stock Price, News & Analysis

Company Overview

PDS Biotechnology Corporation is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immunotherapies for cancer and infectious diseases. Headquartered in Hillsborough, New Jersey, the company leverages its proprietary DPX® platform, a lipid‐based delivery system designed to elicit robust and durable T-cell responses against specific disease targets. By encapsulating peptide antigens in a depot formulation, PDS Biotechnology aims to overcome traditional vaccine limitations and enhance antigen presentation to the immune system.

The company’s lead candidate, PDS0101, is an HPV16‐targeted immunotherapy in clinical trials for the treatment of HPV‐driven malignancies such as head and neck and cervical cancers. In addition to monotherapy studies, PDS0101 is being evaluated in combination with immune checkpoint inhibitors to explore synergistic effects and improve patient outcomes. Beyond oncology, PDS Biotechnology is advancing a tuberculosis vaccine program and other infectious disease candidates, using the same DPX® platform to promote long‐lasting cellular immunity.

Founded in the mid-2000s, PDS Biotechnology has built a development pipeline supported by preclinical research and early‐stage clinical trials conducted in North America and Europe. The company went public in 2020, trading on the NASDAQ under the symbol PDSB, to raise capital for its clinical programs and expand manufacturing capabilities. PDS Biotechnology collaborates with academic centers and industry partners to advance its proprietary technology and accelerate the translation of novel immunotherapies into the clinic.

Guided by a leadership team with extensive experience in biotechnology and immuno‐oncology, PDS Biotechnology continues to refine its DPX® platform and grow its pipeline. The management team draws on decades of scientific, clinical and regulatory expertise to navigate complex development pathways and deliver potential new treatment options for patients with limited therapeutic alternatives.

Key Stats

• Today's Range: $1.20 to $1.33
• 50-Day Range: $1.16 to $1.79
• 52-Week Range: $0.85 to $4.42
• Volume: 409,821 shs
• Average Volume: 473,238 shs
• Market Capitalization: $55.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

PDS Biotechnology Stock Analysis - MarketRank™

PDS Biotechnology scored higher than 39% of companies evaluated by MarketBeat, and ranked 571st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PDS Biotechnology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PDS Biotechnology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PDS Biotechnology has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.79% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in PDS Biotechnology has recently decreased by 31.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PDS Biotechnology does not currently pay a dividend.

Dividend Growth

PDS Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.79% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in PDS Biotechnology has recently decreased by 31.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.13

News Sentiment

PDS Biotechnology has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PDSB on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of PDS Biotechnology is held by insiders.

Percentage Held by Institutions

Only 26.84% of the stock of PDS Biotechnology is held by institutions.

PDSB Stock Analysis - Frequently Asked Questions

How have PDSB shares performed this year?

PDS Biotechnology's stock was trading at $1.63 at the beginning of 2025. Since then, PDSB shares have decreased by 25.2% and is now trading at $1.22.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Corporation (NASDAQ:PDSB) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04.
Read the conference call transcript.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PDS Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PDSB
• CIK: 1472091
• Web: www.pdsbiotech.com
• Phone: (800) 208-3343
• Fax: 908-790-1212
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +637.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.59%
• Return on Assets: -69.15%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.33
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 45,710,000
• Free Float: 41,505,000
• Market Cap: $55.77 million
• Optionable: Optionable
• Beta: 1.21